BS_TDEFAPNH
DNET
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- DNET
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- DNET
- age_years
- 11.025
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.506
- ANGIOGENESIS+0.495
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.397
- KRAS_SIGNALING_UP+0.380
- MYOGENESIS+0.379
- KRAS_SIGNALING_DN+0.377
- HEDGEHOG_SIGNALING+0.369
- COAGULATION+0.366
- INFLAMMATORY_RESPONSE+0.315
- APICAL_SURFACE+0.285
Top 10 suppressed
- G2M_CHECKPOINT-0.623
- E2F_TARGETS-0.593
- MYC_TARGETS_V2-0.571
- MYC_TARGETS_V1-0.551
- MITOTIC_SPINDLE-0.468
- DNA_REPAIR-0.465
- UNFOLDED_PROTEIN_RESPONSE-0.399
- MTORC1_SIGNALING-0.243
- CHOLESTEROL_HOMEOSTASIS-0.232
- PROTEIN_SECRETION-0.225
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1344 | Med | Medulloblastoma | 0.910 |
| 2 | BS_7XRN3CFX | low-grade glioma | — | 0.906 |
| 3 | BS_YB2RXRHT | pilocytic astrocytoma | — | 0.890 |
| 4 | SRR1335707 | GTEX | — | 0.885 |
| 5 | MDT-AP-2130 | Med | Medulloblastoma | 0.880 |
| 6 | TCGA-XF-A9SL-01A-11R-A39I-07 | — | — | 0.880 |
| 7 | R251 | — | — | 0.875 |
| 8 | SRR1359171 | GTEX | — | 0.875 |
| 9 | d3119bbd-8c3d-4f95-863c-a04ae8b18eb9 | — | — | 0.872 |
| 10 | GSM5359443 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.506 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.495 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.397 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.379 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.377 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.369 | Inavolisib | — uncovered |
| COAGULATION | 0.366 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.315 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.285 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.274 | Inavolisib | — uncovered |
| HYPOXIA | 0.227 | Idelalisib | — uncovered |
| COMPLEMENT | 0.215 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.213 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.195 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.186 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.182 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.158 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.144 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |